文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Zagouri 2015 Fulvestrant and male breast cancer
侵权投诉

Zagouri 2015 Fulvestrant and male breast cancer

272

e,ns

ltaoeBmo

o

s

evNNYivrulsareeecs

rstfieo

s

s

-VmeeNYYnoisses

rs

s

eegtchhoessrdetataA

pifo o SfeHNHSFP),yelshntenospooA

sDmg

e(m5522NrlaiS

trF5

.aP224

4pRe

Ps,nestoaspeesR

R

D

sBeirPPSdne

onisit

sd

h

tsLr134ergy

orppareDtPnht,aoervsoumaijeero

sPdhA

acNA

NidetlnbaavtrsouijrT

DPdaHA

s

eoNYNS,ba7

6miuKA

A

ANNNzutse

as

vruittiRtaAsAHPtsNoPN,dese

e

a2vveiibRs

vutt-aaiteEtiaggsnHteeoasNNPxate

e

e

s

vvvTuiii,tttRtiiidassseEtooossPPPab-s

eitnasilloancieytggcianaatiA

B

IsdNIVrIIhtneadaAr,GA

t2

1

Nney

mtgaoelrottlsaiHA

C

AnNDINomre

oghA9

9

2764Td

He,u,en]ls

i5.bet1lsaan[nastlao.itleocayaszavatat1e2

aeBbu-eltaanee

anomlH´g rnbmweid]

o]

atnsaa4m6taarlop1r1AeTNgAeR[a[dCNM123

BreastCancerResTreat(2015)149:269–275

37.5%,III43.8%,IV6.2%.52.9%ofpatientshadagrade3carcinoma,followedbygrade2(35.3%)andgrade1(11.8%).ERwaspositiveinalleligiblecases,PRwaspositiveinthevastmajorityofpatients(93.3%),whereaski-67wasreportedonlyinthestudybyZagourietal.[9].HER2wasnegativeinthemajorityofpatients(82.6%).Adjuvanthormonaltreatmentwasadministeredin87.5%ofcaseswherethisinformationwasprovided(n=16);ofnotein7/23casestherelevantdatawerenotreported.Regardingpreviouslygivenadjuvantchemotherapy,56.25%ofpatientshadreceivedanthracyclineandtaxane-basedchemotherapy,25%hadreceivedanthracyclinealone,6.25%taxanealone,whereas12.5%hadnotreceivedadjuvantchemotherapy;trastuzumabwasco-administeredinonepatientintheadjuvantsetting.

Fulvestrantwasgivenas rstorsecondlinein40%ofpatients,whileasthirdlineorbeyondin60%ofpatients.Inallcaseswherefulvestrantdosewasrepor-ted,itwasequalto250mgmonthlywithloadingdose500mg;ofnote,inonecase[16]fulvestrantwascom-binedwithtrastuzumabadministration(trastuzumabbeyondprogression).79.0%ofpatientsatfulvestrantadministrationhadvisceralmetastases;whereas66.7%ofmalebreastcancerpatientssufferedfrombonemetastases.Regardingbestresponse,in26.1%PRwasachieved,in47.8%ofcasesSDwasrecorded,whereasin26.1%ofpatientsPDwasnoted.ThemedianPFSwasequalto5months.Kaplan–Meiersurvivalestimateregardingprogression-freesurvivalisdepictedinFig.2.Regardingadverseevents,nograde3and4eventswererecorded;ofnote,hot asheswerereportedin18.2%ofmalebreastcancerpatients.

LackofreporteddatawasobservedregardingOSinthemajorityofeligiblestudies;therefore,nopoolingwasundertakeninviewofthedatascarcity.Speci cally,OSwasnotreportedinthestudiesbyAgrawaletal.[15],Carmona-Bayona[16],delaHambaetal.[14],aswellasinfouroutof vepatientsincludedinthestudybyMascietal.[13];notably,the fthpatientinthelatterstudy[13]didnotdiefrombreastcancer.

Table2presentstheresultsofunivariateCoxregressionandunivariatelogisticregressionanalysesregardingPFSandclinicalbene t,respectively.Noassociationswithageatfulvestrantadministration,linesoftreatment,grade,initialstageatdiagnosis,HER2status,PRstatus,adjuvanthormonaltreatment,adjuvantchemotherapy,visceralmetastases,bonemetastases,hot asheswerenoted.InadditiontotheassociationspresentedinTable2,itseemsinterestingtonotethattheoccurrenceofhot ashesdidnotcorrelatewithage(p=0.294,Fisher’sexacttest)despiteanumerictrend(11.1%ofpatientsolderthanthemedianexperiencedhot ashesversuss37.5%ofpatientsyoungerthanthemedian).

上一页第4页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email